Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTI-CLDN-5 ANTIBODY, AND DRUG CONTAINING SAID ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2018/207638
Kind Code:
A1
Abstract:
The problem of providing a novel molecule having high specificity to CLDN-5 and capable of recognizing an extracellular domain of CLDN-5 can be solved by an antibody capable of specifically recognizing the three-dimensional structure or the primary structure of an extracellular domain of Claudin-5 protein.

Inventors:
KONDOH MASUO (JP)
YAGI KIYOHITO (JP)
DOI TAKEFUMI (JP)
OKADA YOSHIAKI (JP)
HASHIMOTO YOSUKE (JP)
SAWASAKI TATSUYA (JP)
TAKEDA HIROYUKI (JP)
ENDO KOHKI (JP)
TAMURA MAKI (JP)
Application Number:
PCT/JP2018/016975
Publication Date:
November 15, 2018
Filing Date:
April 26, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV OSAKA (JP)
UNIV NAT CORP EHIME UNIV (JP)
FUJIFILM WAKO PURE CHEMICAL CORP (JP)
International Classes:
C07K16/28; A61K39/395; A61K47/42; A61K47/68; A61P43/00; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N5/12; C12N15/13
Domestic Patent References:
WO2009028663A12009-03-05
WO2008114733A12008-09-25
WO2016088689A12016-06-09
Foreign References:
US20110064792A12011-03-17
JP2016525558A2016-08-25
JP2016047845A2016-04-07
JP2003524384A2003-08-19
Other References:
LIAO, ZHUANGBIN ET AL.: "Specific binding of a mutated fragment ofClostridium perfringensenterotoxin to endothelial claudin-5 and its modulation of cerebral vascular permeability", NEUROSCIENCE, vol. 327, 13 April 2016 (2016-04-13), pages 53 - 63, XP029535193
NITTA, TAKEHIRO: "Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice", J. CELL BIOL., vol. 161, no. 3, 12 May 2003 (2003-05-12), pages 653 - 660, XP002472300
ESCUDERO-ESPARZA, ASTRID ET AL.: "Claudin-5 is involved in breast cancer cell motility through the N-WASP and ROCK signalling pathways", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 31, no. 43, 2012, pages 1 - 18, XP021117275
PROTZE, JONAS ET AL.: "Directed structural modification of Clostridium perfringens enterotoxin to enhance binding to claudin-5", CELL. MOL. LIFE SCI., vol. 72, 2015, pages 1417 - 1432, XP035471604
MATTHEW CAMPBELLANNA-SOPHIA KIANGPAUL F. KENNACHRISTIAN KERSKENSCHRISTOPH BLAULAURENCE O'DWYERAMANDA TIVNANJULIE ANNE KELLYBRENDA : "RNAi-mediated reversible opening of the blood-brain barrier", THE JOURNAL OF GENE MEDICINE, vol. 10, 2008, pages 930 - 947, XP002536283, DOI: 10.1002/JGM.1211
CHRISTIAN STAATCAROLINE COISNESEBASTIAN DABROWSKISVETLANA M. STAMATOVICANUSKA V. ANDJELKOVICHARTWIG WOLBURGBRITTA ENGELHARDTINGOLF: "Mode of action of claudin peptidomimetics in the transient opening of cellular tight junction barriers", BIOMATERIALS, vol. 54, 2015, pages 9 - 20, XP055343621, DOI: 10.1016/j.biomaterials.2015.03.007
JONAS PROTZEMIRIAM EICHNERANNA PIONTEKSTEFAN DINTERJANROSSAKINGA GRAZYNA BLECHARZPETER VAJKOCZYJOERG PIONTEKGERD KRAUSE: "Directed structural modification of Clostridium perfringens enterotoxin to enhance binding to claudin-5", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 72, 2015, pages 1417 - 1432, XP035471604, DOI: 10.1007/s00018-014-1761-6
KARLIN SALTSCHUL SF: "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes", PROC NATL ACAD SCI USA, vol. 87, 1990, pages 2264 - 2268, XP001030853, DOI: 10.1073/pnas.87.6.2264
KARLINSALTSCHUL SF: "Applications and statistics for multiple high-scoring segments in molecular sequences", PROC NATL ACAD SCI USA, vol. 90, 1993, pages 5873 - 7, XP001030852, DOI: 10.1073/pnas.90.12.5873
"Current protocols in Molecular Biology", 1987, JOHN WILEY AND SONS
See also references of EP 3623384A4
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Download PDF:



 
Previous Patent: SILENCER

Next Patent: CONVEYANCE CART